Alpha 2.0
Login Register
» Authors » C Tracey Lancaster

C Tracey Lancaster

Explore the profile of C Tracey Lancaster including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 41
Followers 0
Related Specialties
Infectious Diseases
Pharmacology
Top 10 Co-Authors
Keith A Pappa
Lisa L Ross
Qiming Liao
Gary E Pakes
Edwin DeJesus
Margaret A Fischl
Winkler G Weinberg
Kimberly Y Smith
Jaime E Hernandez
Richard B Pollard
Published In
AIDS Res Hum Retroviruses
BMC Infect Dis
Antimicrob Agents Chemother
AIDS Res Ther
Affiliations
Soon will be listed here.
Recent Articles
1.
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients
Ross L, Weinberg W, DeJesus E, Fischl M, Horton J, Pappa K, et al.
AIDS Res Hum Retroviruses . 2010 Apr; 26(4):407-17. PMID: 20380480
Population genotyping (PG) can underestimate resistance if resistance-containing low abundance variants go undetected. PG and clonal analysis (CA) results were compared in virologic failures (VFs) from a 48-week clinical trial...
2.
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758
Hicks C, DeJesus E, Sloan L, Sension M, Wohl D, Liao Q, et al.
AIDS Res Hum Retroviruses . 2009 Mar; 25(4):395-403. PMID: 19320570
The long-term efficacy of once-daily (qd) fosamprenavir (FPV) 1400 mg boosted by ritonavir 100 mg (FPV/r100) has not been evaluated previously. A 96-week open-label, randomized, multicenter study compared the efficacy/safety...
3.
Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT
Smith K, Weinberg W, DeJesus E, Fischl M, Liao Q, Ross L, et al.
AIDS Res Ther . 2008 Apr; 5:5. PMID: 18373851
Background: Once-daily (QD) ritonavir 100 mg-boosted fosamprenavir 1400 mg (FPV/r100) or atazanavir 300 mg (ATV/r100), plus tenofovir/emtricitabine (TDF/FTC) 300 mg/200 mg, have not been compared as initial antiretroviral treatment. To...
4.
Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers
Ruane P, Luber A, Wire M, Lou Y, Shelton M, Lancaster C, et al.
Antimicrob Agents Chemother . 2006 Nov; 51(2):560-5. PMID: 17088488
Once-daily (QD) fosamprenavir (FPV) at 1,400 mg boosted with low-dose ritonavir (RTV) at 200 mg is effective when it is used in combination regimens for the initial treatment of human...
5.
Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients
Nadler J, Gathe J, Pollard R, Richmond G, Liao Q, Griffith S, et al.
BMC Infect Dis . 2003 Jun; 3:10. PMID: 12795812
Background: Low-dose ritonavir (RTV) boosts plasma amprenavir (APV) exposure. Little has been published on the efficacy, tolerability, and safety of APV 600 mg/RTV 100 mg (APV600/RTV) twice daily (BID) compared...